Vaccines and Passive Immunity against Candidiasis

摘要: This chapter reviews the rationale for and latest advances in development of passive active immunization against invasive candidal infections. The major form immunosuppression that predisposes to disseminated candidiasis is a defect innate phagocytic activity. Treatment with antibiotics most promising risk factor identify high attack rate vulvovaginal (VVC) as basis enrollment into clinical trials an vaccine. Development vaccine oropharyngeal (OPC) patients human immunodeficiency virus (HIV)/AIDS complicated by host fact effective immune reconstitution therapy now available patients. majority at are those undergoing emergent or elective gastrointestinal cardiac surgery, central venous catheters, receiving broad-spectrum antibiotics, general their care intensive units, including both civilian military trauma abdominal, chest, burn wounds. Passive strategy focusing on β- glucan has been based upon raising protective antibodies actively vaccinating β-glucan conjugated carrier protein. To determine potential Als3-based vaccine, recombinant N terminus Als3p (rAls3p-N) was expressed Saccharomyces cerevisiae purified Ni-agarose affinity purification, same manner described rAls1p-N. concept niche vaccination acutely at-risk restricted geographical areas new idea vaccinology.